Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2, Trial to Investigate the Dose-Response Relationship of a Single Injection of Org 36286 (Corifollitropin Alfa) to Initiate Multiple Follicular Growth in a Controlled Ovarian (Study 38826)(P06055)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Females of couples with an indication for COH and IVF or ICSI;~* \>=18 and \<=39 years of age at the time of signing informed consent;~* BMI \>=18 and \<=29 kg/m\^2;~* Normal menstrual cycle length: 24-35 days;~* Ejaculatory sperm (use of donated and/or frozen sperm is allowed);~* Willing and able to sign informed consent.~Exclusion Criteria:~* History of/or any current (treated) endocrine abnormality;~* History of ovarian hyperstimulation syndrome (OHSS);~* History of/or current polycystic ovary syndrome (PCOS) or current polycystic ovaries according to USS (at least 10 follicles of 2-8 mm in each ovary);~* More than three unsuccessful COH cycles since the last established ongoing pregnancy (if applicable);~* History of non- or low ovarian response to FSH/hMG treatment;~* Any clinically relevant hormone value outside the reference range during the early follicular phase (menstrual cycle day 2-7) as measured by the local laboratory (FSH, LH, E2, P, total T, TSH and prolactin):~* Any clinically relevant abnormal laboratory value;~* Less than 2 ovaries;~* Any ovarian and/or abdominal abnormality interfering with ultrasound examination;~* Contraindications for the use of gonadotropins (e.g. tumors, pregnancy/lactation, undiagnosed vaginal bleeding, hypersensitivity, ovarian cysts);~* Epilepsy, diabetes, cardiovascular, gastro-intestinal, hepatic, renal, pulmonary, or abdominal disease;~* History of presence of alcohol or drug abuse within 12 months prior to signing informed consent;~* Previous use of Org 36286;~* Use of hormonal preparations within 1 month prior to randomization;~* Hypersensitivity to Org 32489 (Puregon®) and/or Org 37462 (Orgalutran®) and/or Pregnyl® or any of their components;~* Administration of investigational drugs within three months prior to signing informed consent.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 60 µg Org 36286 (corifollitropin alfa)
- 2 (Type: EXPERIMENTAL): 120 µg Org 36286 (corifollitropin alfa)
- 3 (Type: EXPERIMENTAL): 180 µg Org 36286 (corifollitropin alfa)
- 4 (Type: ACTIVE_COMPARATOR): Follitropin beta injection

Based on this trial design, predict the completion outcome and termination type (if applicable).